Research programme: AAV-mVChR1 gene therapy - Astellas/CLINO

Drug Profile

Research programme: AAV-mVChR1 gene therapy - Astellas/CLINO

Alternative Names: AAV-mVChR1

Latest Information Update: 03 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tohoku University
  • Developer Astellas Pharma; CLINO Corporation
  • Class
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Retinitis pigmentosa

Most Recent Events

  • 01 Feb 2016 Astellas and CLINO Corporation sign a license agreement for the worldwide development and commercialisation of AAV-mVChR1 for the treatment of Retinitis pigmentosa
  • 01 Feb 2016 Early research in Retinitis pigmentosa in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top